| abstract |
The invention relates to a mutant of factor VIII: C, wherein the new molecule lacks the amino acids Ser⁶⁸⁹¹ to Arg¹⁶⁸⁹. As a result, of the 4 thrombin cleavage sites previously considered essential, only the cleavage site at Arg³⁷² is retained. The cleavage site at Arg¹⁶⁴⁸ is missing, from the cleavage sites at Arg⁷⁴⁰ and Arg¹⁶⁸⁹ the adjacent amino acids are present, the connection of which creates a new cleavage site. In addition to the procoagulant activity and biological half-life, which is very similar to the authentic protein, the new protein has a faster activation by thrombin. |